Lean Rx vs MyDrHank
Two GLP-1 desks, one scoreboard. We put Lean Rx and MyDrHank head-to-head on the published Brief Score — the same six factors, scored the same way.
MyDrHank
The verdict
MyDrHank takes this head-to-head.
MyDrHank scores 74 to 64 on our six-factor Brief Score — A six-shelf prescription telehealth catalog whose GLP-1 price genuinely holds flat as you titrate — but whose every advertised figure is a twelve-month prepay rate, with the month-to-month price published nowhere.
That doesn't make Lean Rx a bad call — it's best for patients wanting compounded glp-1 in injectable, sublingual, or tablet form. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Lean Rx | MyDrHank | |
|---|---|---|
| Brief Score | 64/100 (C) | 74/100 (C) |
| Semaglutide | From $266/mo (starting dose, compounded) | $259/mo (month-to-month; prepay tiers lower) |
| Tirzepatide | From $399/mo (starting dose, compounded) | $349/mo (month-to-month; prepay tiers lower) |
| Coverage | Coverage not published | 44 states (not KS, LA, MS, NM, ND, WV) |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Newnew to the tracker, no prior reading | Newnew to the tracker, no prior reading |
Lean Rx: New to the tracker on 1 August 2026. The published line reads From $266/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
MyDrHank: First reading. The funnel advertises "from $240" tirzepatide and "from $171" semaglutide; both are twelve-month prepay rungs, and the month-to-month rates — $349 and $259 — appear on no page of it.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.